Rapid, efficient, and high-diversity antibody discovery is crucial for modern therapeutic and diagnostic development. Single B-cell screening technology overcomes many bottlenecks encountered in traditional antibody discovery approaches. Biointron's AbDrop™ platform leverages droplet-based microfluidic single B cell screening to provide a fast-track, high-diversity, and species-flexible solution to antibody discovery—bringing candidates from shots to hits in as little as 2–3 months.